Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Pharmaceutical Equivalents

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services.

Journal of the American College of Clinical Pharmacy : JACCP·2026

Same author

National trends in prescription drug expenditures and projections for 2026.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Same author

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.

PharmacoEconomics - open·2026

Same author

A reference genome sequence for the exceptionally long-lived Great Basin bristlecone pine, Pinus longaeva.

G3 (Bethesda, Md.)·2026

Same author

Composition and Function of Gut Microbiome: From Basic Omics to Precision Medicine.

Genes·2026

Same author

Development of an acuity scoring system to proactively address drug shortages and increase supply chain resiliency.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Search research articles

Related Experiment Video

Updated: May 24, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Projecting future drug expenditures--2012.

James M Hoffman¹, Edward Li, Fred Doloresco

¹College of Pharmacy, University of Tennessee Health Science Center, MS, Memphis, TN 38105, USA. james.hoffman@stjude.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists

|February 21, 2012

Summary

U.S. drug expenditures saw a 2.7% rise in 2010, driven by clinic growth and generic drug use. Projections for 2012 indicate a 3-5% increase in total drug spending.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Experiment Videos

Last Updated: May 24, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Area of Science:

Health Economics
Pharmaceutical Policy

Background:

U.S. drug expenditures represent a significant portion of healthcare spending.
Understanding expenditure trends is crucial for healthcare planning and resource allocation.

Purpose of the Study:

To analyze drug expenditure trends in 2010 and 2011.
To discuss factors influencing drug expenditures in 2012.
To project future drug spending across different healthcare settings.

Main Methods:

Analysis of drug expenditure data from the IMS Health National Sales Perspectives database.
Examination of trends in total, hospital, and clinic drug expenditures.
Identification of key factors impacting drug spending.

Main Results:

Total U.S. drug expenditures increased by 2.7% from 2009 to 2010, reaching $307.5 billion.
Clinic drug expenditures grew by 6.0%, while hospital expenditures rose by 1.5% in the same period.
Generic drugs accounted for 78% of retail prescriptions in 2010, moderating overall growth.

Conclusions:

Projected total drug expenditures for 2012 are expected to increase by 3-5%.
Clinic-administered drug expenditures are projected to rise by 5-7%, outpacing hospital drug expenditures (0-2% increase).
Factors like new drug development, generic and biosimilar utilization, and drug shortages will influence future spending.